Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dubodencel - Diakonos Oncology

Next Previous
Drug Profile

Dubodencel - Diakonos Oncology

Alternative Names: Dendritic cell cancer vaccine - Diakonos Oncology; DOC-1021

Latest Information Update: 12 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diakonos Research
  • Developer Baylor College of Medicine; Diakonos Oncology
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Malignant melanoma
  • Phase I Adenocarcinoma; Sarcoma
  • Discontinued Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 06 May 2026 Dubodencel - Diakonos Oncology receives Fast Track designation for Malignant melanoma [Parenteral,Injection] (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA
  • 01 May 2026 Dubodencel - Diakonos Oncology receives Fast Track designation for Multiple myeloma (Inoperable/Unresectable, Metastatic disease) in USA
  • 01 May 2026 Efficacy and pharmacodynamics data from a phase I trial in Glioblastoma released by Diakonos Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top